1. P550: A PHASE 3, RANDOMIZED TRIAL OF MAGROLIMAB IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY (ENHANCE-3). (23rd June 2022) Authors: Daver, N. G.; Liu, K.; Werneke, S.; Rustia, E.; Ramsingh, G.; Vyas, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 449 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P551: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53-MUTANT ACUTE MYELOID LEUKEMIA. (23rd June 2022) Authors: Daver, N. G.; Vyas, P.; Chao, M. P.; Xing, G.; Renard, C.; Ramsingh, G.; Sallman, D. A.; Wei, A. H. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 450 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P552: TREATMENT OUTCOMES IN NEWLY DIAGNOSED, UNTREATED PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS. (23rd June 2022) Authors: Daver, N. G.; Iqbal, S.; Renard, C.; Chan, R. J.; Hasegawa, K.; Hu, H.; Tse, P.; Yan, J.; Zoratti, M. J.; Xie, F.; Ramsingh, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 451 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P553: A PHASE 2, OPEN-LABEL, MULTIARM, MULTICENTER STUDY TO EVALUATE MAGROLIMAB COMBINED WITH ANTILEUKEMIA THERAPIES FOR FIRST-LINE, RELAPSED/REFRACTORY, OR MAINTENANCE TREATMENT OF ACUTE MYELOID LEUKEMIA. (23rd June 2022) Authors: Vyas, P.; Daver, N. G.; Chao, M. P.; Xing, G.; Renard, C.; Ramsingh, G.; Wei, A. H.; Sallman, D. A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 452 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS). (23rd June 2022) Authors: Chen, J. Y.; Johnson, L.; McKenna, K. M.; Choi, T. S.; Duan, J.; Feng, D.; Tsai, J. M.; Garcia-Martin, N.; Sompalli, K.; Maute, R.; Vyas, P.; Majeti, R.; Takimoto, C. H. M.; Liu, J.; Ramsingh, G.; Chao, M. P.; Volkmer, J.-P.; Weissman, I. L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 635 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS. (23rd June 2022) Authors: Daver, N. G.; Vyas, P.; Kambhampati, S.; Al Malki, M. M.; Larson, R.; Asch, A.; Mannis, G.; Chai-Ho, W.; Tanaka, T.; Bradley, T.; Jeyakumar, D.; Wang, E.; Xing, G.; Chao, M.; Ramsingh, G.; Renard, C.; Lal, I.; Zeidner, J.; Sallman, D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗